Position in GUTS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$7,268
-$732,732 QoQ
Shares Held
15,871
-84.1% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
2 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 100.ToString("F0")%
None 0.ToString("F0")%
Common Shares in GUTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026LMR Partners LLP holds $224,816,570 across 60 Biotechnology names. GUTS ranks #60 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
74,661 | $24,703,084 | |
| 2 | ACLX |
Arcellx, Inc.
|
212,495 | $24,398,675 | |
| 3 | TERN |
Terns Pharmaceuticals, Inc.
|
400,000 | $21,088,000 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
324,939 | $18,355,804 | |
| 5 | ARGX |
Argenx SE
|
23,488 | $17,152,112 | |
| 6 | APLS |
Apellis Pharmaceuticals, Inc.
|
403,622 | $16,237,713 | |
| 7 | FOLD |
AMICUS THERAPEUTICS, INC.
|
1,049,700 | $15,178,662 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
130,000 | $12,642,500 |
All Filings in GUTS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $7,268 | 15,871 | Shares | Other | 2026-05-15 | |
| 2024-03-31 | $740,000 | 100,000 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||